Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)

This study is testing whether adding radiation therapy after surgery (postoperative radiotherapy) to immunotherapy and chemotherapy improves outcomes in people with non-small cell lung cancer (NSCLC) who had multiple lymph node metastases found after surgery. **You may be eligible if...** - You are 18 to 75 years old - You have had surgery for non-small cell lung cancer and pathology found at least 3 lymph node metastases in the mediastinum (N2 disease) - You have not had any prior radiotherapy, chemotherapy, or immunotherapy - You are in good physical condition (ECOG 0–2) with an expected survival of 3 months or more - Your major organ function is normal **You may NOT be eligible if...** - You have a known or suspected autoimmune disease - You have had an organ transplant or are immunocompromised (including HIV-positive) - You have interstitial lung disease or severe lung problems - You have poorly controlled heart disease (significant heart failure, recent heart attack, uncontrolled arrhythmia) - You have active hepatitis B or C Talk to your doctor to see if this trial is right for you.